Recently, therapies targeting constitutive KRAS activation were shown to extend PFS for patients with NSCLC and CRC harboring KRAS G12C mutations, including adagrasib (CRC and NSCLC) [44, 45] and sotorasib (NSCLC) [46]. Here, KRAS is linked to non-small cell lung carcinoma.